Anita Szajek, Ph.D., principal scientific liaison to USP’s Expert Panel on Therapeutic Peptides, examines therapeutic peptides, the transition from recombinant to synthetic manufacturing routes, and regulatory and quality-related questions.
Everything I have learned and worked toward for pretty much my entire scientific career culminates in the Chief Science Officer role at USP.
Particulate matter in injectable drug products have been the reason for many recent drug recalls. In this blog post, Desmond Hunt, Ph.D., discusses sources of particulate matter and how to control them in the manufacturing process.
Today, peptides represent one of the fastest growing segments in the pharmaceutical market. Hence, being able to manufacture peptides that are consistent in makeup and quality is an important priority for manufacturers of this drug class. This article discusses how the global pharmaceutical landscape continues to transform and how quality standards will play a growing role in the manufacture of these drugs.